EU Industry Fights Back On Ashwagandha Safety
Kerry-led campaign will address “prevailing myths and misinformation” that have led some European regulators to advise against ashwagandha use.
HBW Insight - May 7, 2026

Pfizer Builds Out Separate Biosimilars Division
As Pfizer continues to focus on its commercial execution, the pharma giant placed biosimilars and sterile injectables under a new dedicated division.
Generics Bulletin - May 7, 2026

Challenges Abound To Sustain European Biosimilars ‘Advantage’
As Europe marks 20 years since its first biosimilar approval, Medicines for Europe warned that future growth will depend on smarter regulation, sustainable competition and stronger industrial policy amid mounting concern over the EU’s evolving biotech framework.
Generics Bulletin - May 7, 2026

Medtech AI Act Simplification Push Fails At Last Hurdle
EU walks back proposals for simpler AI medical device rules after pushback.
Medtech Insight - May 7, 2026

Angelini’s $4.1bn Catalyst Deal Opens Door To US Rare Disease Market
The deal advances Angelini’s broader strategy of building scale in brain health and rare neurological disorders through acquisitions, licensing and partnerships.
Scrip - May 7, 2026

Solventum Bets On 20 Product Launches To Power Post-3M Growth
Solventum plans nearly 20 product launches in two years, aiming to "reduce risk" of its post-3M growth, with an AI-powered health information system driving further expansion.
Medtech Insight - May 7, 2026

Roche To Acquire PathAI, Signaling Intensifying AI Diagnostics Race
The Swiss giant will pay up to $1.05bn for digital pathology firm PathAI, in a deal that reflects the surging market value of AI diagnostic platforms.
Medtech Insight - May 7, 2026

Breakthrough Devices Bring New Flexibility And Scrutiny For Notified Bodies
BSI says new EMA pathway is needed to address innovation gap with US and meet patient needs.
Medtech Insight - May 7, 2026

Safety Not A Trade-Off For Innovation In MDR, Says Commission’s Giorgio
The European Commission's Flora Giorgio clarified misconceptions around proposed changes to MDR and IVDR at RAPS Euro Convergence 2026.
Medtech Insight - May 7, 2026

Forward-Firing Catheters, Carotid Balloons, And Valve Crackers: Where IVL Goes Next
Shockwave's Javelin abandons the balloon for a rigid-tip emitter, FastWave is designing around physician pain points, and Boston Scientific's FRACTURE IDE data drops at EuroPCR—each betting on a different path to dethrone first-generation IVL.
Medtech Insight - May 7, 2026

Stelara Biosimilars Get A Boost From CVS Formulary Changes
Formulary changes announced by CVS Health promise to offer wider access to ustekinumab biosimilars over the reference brand Stelara. Meanwhile, similar priority is also being given to Tysabri (natalizumab) and Soliris (eculizumab) rivals.
Generics Bulletin - May 7, 2026

Q&A: How Chinese Biopharma Is Navigating Western Regulatory Markets
As Chinese biopharma companies move from domestic success to global ambition, the regulatory path into Western markets remains complex and often underestimated.
In Vivo - May 7, 2026

How A Cigarette Legal Battle Could Change AI Medtech Regulation
An EU Court of Justice ruling means standards medtech companies must follow under the AI Act could be free to access.
In Vivo - May 7, 2026

Proposed Rule Would Replace ‘Gender’ With ‘Sex’ In US FDA Regulations
The move appears to be another step in the Trump Administration’s diversity, equity and inclusion purge that already has impacted FDA guidances and webpages.
HBW Insight - May 7, 2026

‘Challenging Market Environment’ Slows Perrigo As It Becomes ‘More Focused, Disciplined, Consistent’
CEO Patrick Locwood-Taylor says as Perrigo is “making steady progress in building a more focused, disciplined, and consistent” firm, “we are starting to look at pricing, depending on what happens with other commodity prices.”
HBW Insight - May 7, 2026

Coty: Middle East Conflict Drags Top Line
New York-based Coty reported that the Middle East conflict is expected to shave 2% to 3% off fiscal fourth quarter sales.
HBW Insight - May 7, 2026